Previous Section
Clinical Trials
21. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
- Author
- Kroger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A;
- Institution
- Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de
- Journal
- Bone Marrow Transplant. 2006 Feb;37(4):339-44.
- Abstract URL
- Click here to view abstract
22. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
- Author
- Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D; Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D;
- Institution
- University of Cologne, Cologne, Germany. oliver.cornely@uni-koeln.de
- Journal
- N Engl J Med. 2007 Jan 25;356(4):348-59.
- Abstract URL
- Click here to view abstract
23. Treatment of myelodysplastic syndrome with cyclosporin A.
- Author
- Chen S; Jiang B; Da W; Gong M; Guan M;
- Institution
- Department of Oncology, Peking Union Medical College (PUMC), Hospital No.1, Beijing, China. chen.sc@medmail.com.cn
- Journal
- Int J Hematol. 2007 Jan;85(1):11-7.
- Abstract URL
- Click here to view abstract
24. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
- Author
- Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB; Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB;
- Institution
- Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. smallt@mskcc.org
- Journal
- Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.
- Abstract URL
- Click here to view abstract
25. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
- Author
- Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
- Institution
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
- Journal
- Cancer. 2006 Aug 15;107(4):767-72.
- Abstract URL
- Click here to view abstract
26. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
- Author
- Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ; Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ;
- Institution
- Department of Haematological Medicine, Kings College London and Kings College Hospital, UK.
- Journal
- Br J Haematol. 2006 Oct;135(2):201-9. Epub 2006 Aug 25.
- Abstract URL
- Click here to view abstract
27. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
- Author
- List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
- Institution
- University of South Florida College of Medicine and Malignant Hematology Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9497, USA. heberten@moffitt.usf.edu
- Journal
- N Engl J Med. 2006 Oct 5;355(14):1456-65.
- Abstract URL
- Click here to view abstract
28. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
- Author
- Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
- Institution
- Haematology Services, University of Miguel Servet Hospital, Zaragoza, Spain. pgiraldo@salud.aragon.es
- Journal
- Cancer. 2006 Dec 15;107(12):2807-16.
- Abstract URL
- Click here to view abstract
29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
- Author
- Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
- Journal
- Cancer. 2007 Jan 15;109(2):265-73.
- Abstract URL
- Click here to view abstract
